Patient Capital Management Portfolio in 2026: Top Holdings & Recent Changes
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Patient Capital Management continues to showcase disciplined value investing with a mix of tech exposure and opportunistic bets on healthcare and cyclical sectors. Their $2.59B portfolio in Q4 2025 reflects measured adjustments, including significant increases in biotech and cruise lines while trimming leading tech names, signaling confidence in undervalued recovery plays across a 40-position portfolio.
Portfolio Snapshot: Balanced Concentration with Patient Precision
Portfolio Highlights (Q4 2025): - Market Value: $2,590.7M - Top 10 Holdings: 49.2% - Portfolio Size: 40 -1 - Average Holding Period: 10 quarters - Turnover: 12.5%
The Patient Capital Management portfolio maintains a balanced approach, with the top 10 holdings commanding 49.2% of the total $2.59 billion value. This concentration level—neither ultra-focused nor overly diversified—allows for meaningful bets on high-conviction ideas while spreading risk across 40 positions, one fewer than the prior quarter. The average holding period of 10 quarters underscores a patient, long-term strategy, aligning with the firm's name and philosophy of waiting for intrinsic value to materialize.
Turnover at 12.5% indicates low churn, with changes primarily in the top ranks rather than wholesale overhauls. This measured activity in the Q4 2025 portfolio suggests confidence in core holdings while capitalizing on perceived mispricings in select areas like healthcare and consumer cyclical stocks. The slight reduction in portfolio size hints at consolidation, potentially freeing capital for future opportunities in undervalued names.
Top Positions Breakdown: Tech Trims Meet Healthcare and Cyclical Bets
The portfolio's leading position is Alphabet Inc. (GOOGL) at 7.0%, though Patient Capital reduced it by 5.17% to $182.1M. Financials follow with CITIGROUP INC at 5.8% $150.7M, trimmed by 1.42%, while Amazon.com, Inc. (AMZN) saw a modest 0.10% addition to reach 5.0% $129.8M. Healthcare gains momentum with ROYALTY PHARMA PLC boosted 6.92% to 5.0% $128.8M and UNITEDHEALTH GROUP INC slightly reduced by 0.83% to 4.7% $121.6M.
Further down, QXO Inc (QXO) holds 4.8% $124.8M after a 1.04% cut, complemented by NVIDIA Corporation (NVDA) added 0.97% to 4.6% $119.1M. Cyclicals shine with Norwegian Cruise Line Holdings Ltd. (NCLH) surging 16.28% to 4.6% $118.5M, and biotech standout BIOGEN INC dramatically increased 45.31% to 3.9% $101.4M. Rounding out changes, CVS Health Corporation (CVS) dipped 0.68% to 3.8% $97.7M. These moves highlight a portfolio blending enduring tech leaders with aggressive adds in recovering sectors.
What the Portfolio Reveals About Patient Capital's Strategy
Patient Capital's Q4 adjustments reveal a strategy favoring quality businesses with recovery potential over pure growth chasers. Notable adds in NCLH 16.28% and BIOGEN INC 45.31% point to opportunistic bets on cyclical and biotech rebounds, sectors offering asymmetric upside when undervalued.
- Sector Focus: Heavy tech exposure (GOOGL, AMZN, NVDA) balanced by healthcare (Royalty Pharma, Biogen, UnitedHealth, CVS) and financials (Citigroup), with cyclicals like NCLH adding diversification.
- Risk Management: Trims in top tech names like GOOGL 5.17% and CITIGROUP INC suggest profit-taking amid valuations, while low turnover 12.5% emphasizes stability.
- Geographic Concentration: Primarily U.S.-centric with global giants like Alphabet and Amazon, minimizing emerging market risks.
- Quality Over Growth: Long 10-quarter hold periods favor durable moats in healthcare and tech, avoiding high-flyers without fundamentals.
This mix positions the portfolio for resilience in volatile markets, prioritizing intrinsic value realization.
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
Portfolio Concentration Analysis
| Position | Value | % of Portfolio | Recent Change |
|---|---|---|---|
| Alphabet Inc. | $182.1M | 7.0% | Reduce 5.17% |
| CITIGROUP INC | $150.7M | 5.8% | Reduce 1.42% |
| Amazon.com, Inc. | $129.8M | 5.0% | Add 0.10% |
| ROYALTY PHARMA PLC | $128.8M | 5.0% | Add 6.92% |
| QXO Inc | $124.8M | 4.8% | Reduce 1.04% |
| UNITEDHEALTH GROUP INC | $121.6M | 4.7% | Reduce 0.83% |
| NVIDIA Corporation | $119.1M | 4.6% | Add 0.97% |
| Norwegian Cruise Line Holdings Ltd. | $118.5M | 4.6% | Add 16.28% |
| BIOGEN INC | $101.4M | 3.9% | Add 45.31% |
| CVS Health Corporation | $97.7M | 3.8% | Reduce 0.68% |
The top 10 holdings represent 49.2% of the portfolio, with no single position exceeding 7.0%, demonstrating thoughtful diversification within concentration. Trims in leaders like Alphabet and Citigroup freed capital for outsized adds in Biogen 45.31% and NCLH 16.28%, suggesting tactical reallocation toward higher-conviction undervalued plays. This table underscores Patient Capital's precision: modest tweaks in mega-caps paired with bold increases in recovery names, maintaining balance across tech, healthcare, and cyclicals.
Investment Lessons from Patient Capital Management
Patient Capital Management's Q4 2025 moves offer timeless principles for value investors:
- Patience Pays in Position Sizing: Average 10-quarter holds show conviction trumps short-term noise; dramatic adds like Biogen 45.31% reward waiting for mispricings.
- Trim Winners, Double Down on Value: Reductions in GOOGL 5.17% and NVDA adds 0.97% balance growth with opportunities like NCLH.
- Sector Rotation with Discipline: Low 12.5% turnover amid portfolio shrinkage (40 positions) highlights focus on quality cyclicals and biotech over hype.
- Concentration Without Overreach: 49.2% in top 10 allows impact without excessive risk, ideal for navigating 2025's uncertainties.
These lessons emphasize understanding businesses deeply before scaling.
Looking Ahead: What Comes Next?
With turnover at 12.5% and a trimmed portfolio size, Patient Capital likely holds dry powder for new undervalued entries, especially if healthcare and cruise recoveries accelerate. Current positioning in NVDA and Amazon sets up for AI/e-commerce tailwinds, while Biogen and NCLH could benefit from economic softening or sector catalysts. In a potentially range-bound 2026 market, this setup favors resilient quality names, with opportunities in further financial or energy dips aligning with their patient style.
FAQ about Patient Capital Management Portfolio
Q: What are the biggest changes in Patient Capital's Q4 2025 13F filing?
A: Key moves include a 45.31% add to BIOGEN INC, 16.28% increase in NCLH, and 6.92% boost to ROYALTY PHARMA PLC, offset by trims in GOOGL 5.17% and Citigroup 1.42%.
Q: Why does Patient Capital keep a 49.2% concentration in top 10 holdings?
A: This reflects high-conviction investing in quality names like tech and healthcare, balancing impact with 40 total positions to manage risk—classic value discipline over broad indexing.
Q: What sectors dominate Patient Capital's strategy?
A: Tech (GOOGL, AMZN, NVDA), healthcare (Royalty Pharma, Biogen, UnitedHealth, CVS), financials (Citigroup), and cyclicals (NCLH), showing a focus on durable moats with recovery potential.
Q: How can I track Patient Capital Management's portfolio like a pro?
A: Use ValueSense's superinvestor tracker at https://valuesense.io/superinvestors/patient-capital for real-time 13F updates. Note the 45-day filing lag means positions may evolve post-report—combine with intrinsic value tools for your analysis.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2026)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!